New KCA issueTranslating Metabolic Reporgramming into New Targets for Kidney CancerKidney Cancer pre-press articlesPerioperative Systemic Therapy for Metastatic Renal Cell CarcinomaTherapeutic Sequencing in Metastatic Renal Cell CarcinomaRationale to prime the immune system

Following on from the launch Kidney Cancer in summer 2017, we are now pleased to announce publication of a new issue of the journal. Click on the banner image to go straight to the issue!

Kidney cancer is a “metabolic disease” and clear cell renal cell carcinoma (ccRCC) is ripe for data mining using multiple omics approaches. The figure shows targeted metabolic reprogramming in ccRCC. From: OA Aboud and RH Weiss, Kidney Cancer, vol. 1, no. 2, pp. 93-97, 2017


Axial, coronal, and sagittal CT images of the patient’s abdomen and pelvis revealing metastatic disease at different time points during his therapy. From: Nakajima et al., Kidney Cancer, vol. 1, no. 1, pp. 83-88, 2017

Renal cell carcinoma's disease biology: inactivated VHL gene leads to overexpression of HIF. Genes activated by HIF transcript growth factors such as VEGF, PDGF and FGF. From: Maia et al., Kidney Cancer, vol. 1, no. 1, pp. 15-29, 2017

Schematic of early-phase clinical trial for presurgical systemic antiangiogenic therapy in metastatic RCC. From: Pilié and Jonasch, Kidney Cancer, vol. 1, no. 1, pp. 57-64, 2017

Rationale to prime the immune system with PD-1 blockade prior to nephrectomy. From: Harshman et al., Kidney Cancer, vol. 1, no. 1, pp. 31-40, 2017

Welcome to Kidney Cancer

Editorial Board

Primo Nery Lara

Primo N. Lara Jr, MD

University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA


Peter Mulder

Peter Mulders, MD, PhD

Radboud UMC Nijmegen,The Netherlands



Submission Guidelines




Authors are requested to submit their manuscript electronically to the online submission system msTracker. Note that the manuscript should be uploaded as one file with tables and figures included.


No front page content has been created yet.